- CODEN : IAJPBB
- issn 2349-7750
TITLE:
TO DETERMINE THE EFFECTIVENESS OF RIFAXIMIN FOR HEPATIC ENCEPHALOPATHY PATIENTS WITH CHRONIC LIVER DISEASE
AUTHORS:
Dr Sara Mandokhail, Dr Kaynat Fatima, Dr Rabia Nasir Kakar
ABSTRACT:
Objective: Hepatic encephalopathy (HE) is a reversible neuro-mental disorders related with ceaseless and intense liver brokenness. It is portrayed by subjective and engine shortfalls of fluctuating seriousness. Aim of the study was to evaluate the effects and outcomes of rifaximin for the treatment of hepatic encephalopathy with chronic liver disease patients. Study Design: Prospective/Randomized controlled trial study. Place and Duration of Study: This study was conducted at the Department of Medicine, Civil Hospital Quetta from March 2020 to March 2020. Materials and Methods: Eighty four patients of both genders whom were diagnosed with hepatic encephalopathy with chronic liver disease were including in this study. All the patients were divided into two groups, Group A included 42 patients and received treatment rifaximin with lactulose, Group B (control group) included 42 patients receiving placebo with lactulose. Follow-up was taken at 15 days or at discharge. Hepatic encephalopathy index and Child-Turcotte-Pugh (CTP) score and model for end-stage liver disease (MELD) were recorded to examine the outcome of treatment. Results: In group A 30 patients were males and 12 were females while in Group B, 32 patients were males and 10 patients were females. In Group A, 34 patients were ages <60 years while 8 patients had ages >60 years, In Group B, 33 patients were ages <60 years and 9 patients were ages >60 years. At start of treatment Child-Turcotte-Pugh score p-value 0.467 and model for end-stage liver disease index p-value 0.874 were not statistically significant difference between two groups. Toward the finish of treatment there was noteworthy distinction discovered identified with hepatic encephalopathy file p-esteem 0.039 and model for end-stage liver ailment file p-esteem <0.05 than fake treatment gathering. Youngster Turcotte-Pugh score 0.621 was additionally lower in rifaximin bunch than Group B. Conclusion: The use of rifaximin with lactulose for the treatment of hepatic encephalopathy resulted better outcome than placebo with respect to model for end-stage liver disease index and hospital stay. Key Word: Rifaximin, Chronic liver disease, Hepatic encephalopathy
FULL TEXT
<Approved Journal
NLM ID:101711216 [Serial]
Included in EuroPub database
ICV 2015 - 61.16
Indexed In
S.J Impact Factor:7.157
cosmos Impact Factor:4.153
ICMJE Recommendations
IP Indexing Impact Factor: 2.76
Cover Page
